<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 425
FILED BY CURIS, INC.
PURSUANT TO RULE 425 UNDER THE SECURITIES ACT OF 1933
SUBJECT COMPANY: CURIS, INC.
Date of Report: August 1, 2000
CONTACTS
for Curis, Inc.: for Noonan / Russo Communications:
William B. Boni Anthony Russo
(617) 876-0086, ext. 462 (212) 696-4455, ext. 202
or
Renee Connolly
(212) 696-4455, ext. 227
The statements in this presentation that are not historical facts are forward-
looking statements that involve risks and uncertainties including, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development, regulatory approval and commercialization, the
impact of competitive products, patents, patent litigation, product liability,
third party reimbursement, and other risks and uncertainties associated with the
biotechnology industry and mergers generally. For additional factors that could
cause actual results to differ materially, please refer to the risk factors
section of the Curis joint proxy statement/prospectus filed with the Securities
and Exchange Commission on June 19, 2000.
Investors and security holders are advised to read the joint proxy
statement/prospectus regarding the business combination transaction referenced
in the foregoing information, because it will contain important information.
Such joint proxy statement/prospectus was filed with the Securities and Exchange
Commission by Curis, Inc. on June 19, 2000. Investors and security holders may
obtain a free copy of the joint proxy statement/prospectus and other documents
filed by Curis, Inc. at the Commission's web site at www.sec.gov. The joint
proxy statement/prospectus and such other documents may also be obtained
directly from Curis, Inc.
<PAGE>
Curis Slide Presentation:
CURIS, INC,
PRESENTATION REGARDING PERIPHERAL NEUROPATHY
SAFE HARBOR STATEMENT
---------------------
The statements in this presentation that are not historical facts are forward-
looking statements that involve risks and uncertainties including, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development, regulatory approval and commercialization, the
impact of competitive products, patents, patent litigation, product liability,
third party reimbursement, and other risks and uncertainties associated with the
biotechnology industry and mergers generally. For additional factors that could
cause actual results to differ materially, please refer to the risk factors
section of the Curis joint proxy statement/prospectus filed with the Securities
and Exchange Commission on June 19, 2000.
Investors and security holders are advised to read the joint proxy
statement/prospectus regarding the business combination transaction referenced
in the foregoing information, because it will contain important information.
Such joint proxy statement/prospectus was filed with the Securities and Exchange
Commission by Curis, Inc. on June 19, 2000. Investors and security holders may
obtain a free copy of the joint proxy statement/prospectus and other documents
filed by Curis, Inc. at the Commission's web site at www.sec.gov. The joint
proxy statement/prospectus and such other documents may also be obtained
directly from Curis, Inc.
PERIPHERAL NERVE CELLS
----------------------
Slide includes a diagram showing the structure and functional types of nerve
cells.
DHH AND PERIPHERAL NERVE FUNCTION
---------------------------------
Slide includes a diagram showing the expression of hedgehog protein by Schwann
Cells, their effect on perinuerial cells and on nerve growth.
SUPPORT CELLS IN ADULT PERIPHERAL NERVE EXPRESS DHH RECEPTOR
------------------------------------------------------------
Slide includes an image showing the expression of Desert Hedgehog protein in
adult peripheral nerve cells.
STRUCTURAL COMPARISON OF SCIATIC NERVE
--------------------------------------
Slide includes two images showing (1) Normal Sciatic Nerve Cells and (2) Desert
Hedgehog Knock-Out Nerve Cells.
FUNCTIONAL DEFICIT IN PERIPHERAL NERVE OF DHH KNOCK-OUT MICE
------------------------------------------------------------
Slide includes a graph showing significant loss of nerve conduction velocity in
Desert Hedgehog Knock-Out Mice.
DHH IS A MITOGEN FOR PERIPHERAL NERVE SUPPORT CELLS
---------------------------------------------------
Slide includes a graph showing increasing cell division with increasing Desert
Hedgehog Protein.
